What one share of Clinuvel Pharmaceuticals holds
Headquartered in Melbourne, Australia, and with operations in Europe, Singapore, and the U.S., Clinuvel is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations.
Clinuvel Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.27 |
|---|---|
| Profit | $0.46 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.23 |
| Dividends | $0.03 |
| Cash and investments | $0.28 |
| Book value | $3.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $1.13 | $0.46 | $0.07 | $0.39 | — | $2.71 |
| 2025 | $1.21 | $0.46 | $0.00 | $0.54 | — | $3.13 |
| 2026 | $1.27 | $0.46 | $0.02 | $0.23 | — | $3.74 |
Common questions about Clinuvel Pharmaceuticals
How much does one share of Clinuvel Pharmaceuticals earn?
Over its latest fiscal year, each share of Clinuvel Pharmaceuticals earned $0.46 of profit on $1.27 of sales, keeping about 36¢ of every $1 (profit margin).
Does Clinuvel Pharmaceuticals pay a dividend?
Yes. Clinuvel Pharmaceuticals paid $0.03 per share in dividends over its latest fiscal year. That’s about 7¢ of each $1 of profit (payout ratio).
What is Clinuvel Pharmaceuticals’s book value per share?
Clinuvel Pharmaceuticals’s book value is $3.74 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Clinuvel Pharmaceuticals have?
Each share of Clinuvel Pharmaceuticals has $0.28 of cash and investments, as of June 30, 2026.
What is Clinuvel Pharmaceuticals’s free cash flow per share?
$0.23 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.